Fig. 1 | Signal Transduction and Targeted Therapy

Fig. 1

From: Integrate and conquer: pan-cancer proteogenomics uncovers cancer vulnerabilities and therapeutic opportunities

Fig. 1

Computational workflow for data integration of public databases to identify new drug targets. Top: Computational process of data integration between CPTAC data and public online genomic and cell line databases, drug repositories and online resources for protein and peptide validation. (CNV: cell number variation) Lower left: Comparison of normal and tumor samples led to the identification and validation of partner genes after loss of function (LoF) of tumor suppressor genes (TSGs), protein dependencies that led to loss of fitness in cancer cell lines, KRAS mutants neoantigens and tumor associated antigens that show highly restricted expression in normal tissues. Lower right: Potential clinical implications after this study include drug repurposing, development of new small-molecules drugs or drug-antibody conjugates, novel therapies for companion diagnostics and access to a user-friendly web portal for the identified targets. Partially created with BioRender.com and Adobe Illustrator. Adapted from Savage, S.R. et al.1

Back to article page